Completed · Netherlands · Pharma and biotech
Ambrose Healthcare acquires AM-Pharma.
UK rare-disease company Ambrose Healthcare (Cambridge) acquired 100% of Utrecht-based AM-Pharma, developer of the enzyme therapy ilofotase alfa for hypophosphatasia, announced on 20 October 2026. The deal gives Ambrose its first European base. The deal completed on 20 October 2026.
Announced 20 October 2026 · Day 100 on 28 January 2027
- Buyer
- Ambrose Healthcare ·Cambridge, United Kingdom
- Target
- AM-Pharma B.V. ·Utrecht, Netherlands
- Type
- Acquisition
- Announced
- 20 October 2026
- Completed
- 20 October 2026
- Value
- up to EUR 161 million
- People
- Not stated in the release
- Last checked
- 28 October 2026
The people side in the Netherlands
- A Dutch company with 50 or more employees has a works council with a formal advice right on a transfer of control. Works Councils Act (Wet op de ondernemingsraden), articles 2 and 25
- Where 50 or more people work in the Netherlands, the SER Merger Code has unions informed before announcement and agreement. SER Merger Code 2015 (SER-Fusiegedragsregels 2015), articles 2, 3 and 4
- Vital providers and sensitive technologies add a Vifo Act review of eight weeks, which can be extended by up to six months. Investment, Mergers and Acquisitions Security Screening Act (Wet veiligheidstoets investeringen, fusies en overnames), article 12
- A foreign employer without a Dutch entity must normally still register to pay Dutch social insurance premiums. Business.gov.nl: National and employee insurance schemes (Dutch social security)
- In an asset or business transfer, staff move to the buyer on their existing terms and collective agreement; the seller stays jointly liable for one year. Business.gov.nl (Ministry of Social Affairs and Employment): Company takeover and employee rights
- Where the deal needs EU merger clearance, the buyer may not implement it before clearance. EU Merger Regulation (Council Regulation (EC) No 139/2004), article 7
Related deals
- 16 Oct
Apax Partners LLPto
Odido Netherlands Holding B.V.deal page: Apax agrees to acquire OdidoSigned
not statedSigningDay 100 - 21 Oct
EQT ABto
QIAGEN N.V.deal page: EQT agrees to acquire QIAGENSigned
not statedSigningDay 100 - 19 Oct
Silgan Holdings Inc.to
Trivium Packaging B.V.deal page: Silgan to acquire TriviumAnnounced
7,200SigningDay 100 - 19 Oct
Merck KGaAto
Silence Therapeutics plcdeal page: Merck KGaA agrees to acquire Silence TherapeuticsSigned
not statedSigningDay 100